BRAF and non-small cell lung carcinoma: For instance, in non-small cell lung cancer patients with no available tumor biopsy, blood is the only source for detecting genetic alterations, including EGFR, KRAS, BRAF, PIK3CA mutations, and ALK rearrangements [11,30].